[vc_row css=”.vc_custom_1643256553022{margin-top: 30px !important;}”][vc_column width=”1/2″][vc_single_image image=”4933″ img_size=”full” alignment=”center”][/vc_column][vc_column width=”1/2″][vc_column_text]
Options for Stage III Melanoma
New Update!
The Decision-Support Tool contains updated information your patients need to know about outcomes for Stage III melanoma, long-term data for adjuvant therapies, and additional resources, including content specific for caregivers.
Welcome to this pamphlet, Options for Stage III Melanoma: Making the Decision That’s Right for You. You can use this pamphlet to discuss options for managing Stage III melanoma with your patients. It provides an in-depth discussion of high-risk melanoma, substages of stage III disease, and adjuvant therapy options vs active surveillance. This pamphlet was produced through a collaboration of AIM at Melanoma Foundation and Terranova Medica, LLC. Faculty oversight was provided by
- Eric D. Whitman, MD, FACS; Medical Director of Atlantic Health System’s Oncology Service Line; Morristown, New Jersey
- Janice M. Mehnert, MD; Regional Phase 1 Clinical Program Director; Medical Oncologist; Rutgers Cancer Institute; New Brunswick, New Jersey
- Lisa A. Kottschade, APRN, MSN, CNP; Coordinator, Outpatient Oncology Melanoma Practice; Mayo Clinic; Rochester, Minnesota
The development of this pamphlet was supported by unrestricted educational grants from Bristol Myers Squibb; Merck & Co., Inc; and Novartis Pharmaceuticals Corporation.
We hope you find this pamphlet helpful in supporting shared decision-making for your patients with Stage III melanoma.[/vc_column_text][vc_btn title=”Click Here to Download” color=”violet” link=”url:https%3A%2F%2Faimwithimmuno.wpengine.com%2Fwp-content%2Fuploads%2F2021%2F03%2FStage-III-Melanoma-Diagnosis-Final.pdf|target:_blank”][/vc_column][/vc_row]